Interestingly, both brivanib and cediranib, dual inhibitors of VEGFR and PDGFR 95-98, correspond with stronger interactions between MED6-high tumor cells and stromal cells via VEGFR and PDGFR. The gene discussed is KDR; the disease is neoplasm.